IP Library Granted Patent US 10,080,770
Granted Patent B2
US 10,080,770 · App. 15/720,859 · Granted Sep 25, 2018

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

Inventors: Antoine Turzi (Mollens, CH); Donald Francois Du Toit (Western Cape, ZA)
Assignee: RegenLab USA LLC
A61K35/19A61K8/981A61K8/983A61K35/14A61K35/15A61K35/16A61K35/18A61K35/28A61K35/30A61K35/32A61K35/34A61K35/35A61K35/36A61K35/38A61K35/39A61K35/51A61K38/363A61K38/4833A61L24/0005A61L24/106A61L26/0042A61L26/0057A61L27/3691A61L27/3886A61M1/3693A61Q19/00A61Q19/08A61K2300/00A61K2800/87A61L2430/02A61M2202/0427C12Y304/21005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,080,770
App. No.
15/720,859
Granted
Sep 25, 2018
Kind
B2
Abstract

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

Claims (42)

1. A method of treating a patient with platelet rich plasma, said method comprising:

withdrawing blood from said patient;

centrifuging said blood in a centrifugation tube containing only two additives,

said two additives being an anticoagulant and a thixotropic gel to separate and obtain platelet rich plasma, wherein said centrifuging is performed one time in said method for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;

removing said platelet rich plasma obtained from said centrifugation tube; and

administering said platelet rich plasma to said patient.

2. The method of claim 1 , wherein said centrifuging comprises centrifuging said tube at a force between 1500×g and 2000×g for 3 to 10 minutes.

3. The method of claim 1 , wherein said centrifuging comprises centrifuging said tube at a force of at least 1500×g for at least 8 minutes.

4. The method of claim 1 , further comprising separating said platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.

5. The method of claim 4 , further comprising re-suspending said platelet rich plasma in said tube, wherein said re-suspending follows said separating said platelet rich plasma.

6. The method of claim 1 , further comprising admixing the platelet rich plasma with a coagulation activator, wherein the coagulation activator comprises at least one of: a thrombin activator, a fibrinogen activator, calcium, a calcium salt, CaCl 2 , CaCO 3 , CaSO 4 , sodium, batroxobin, thrombin, a thrombin enriched preparation, an autologous thrombin, and an autologous thrombin serum.

7. The method of claim 6 , wherein said platelet rich plasma is admixed with said coagulation activator at a ratio of 10:1 to 10:3.

8. The method of claim 6 , wherein said admixing comprises delivering said platelet rich plasma and said coagulation activator at the same time so that said platelet rich plasma and said coagulation activator mix and polymerize upon contact with said patient.

9. The method of claim 6 , further comprising:

repeating said withdrawing, said centrifuging, said removing, said admixing, and said administering at 7±1 days after a previous treatment.

10. The method of claim 1 , further comprising:

extracting keratinocytes from said patient and re-suspending said keratinocytes in said platelet rich plasma before said administering.

11. The method of claim 1 , wherein said administering comprises injecting said platelet rich plasma subcutaneously in a wrinkle groove as wrinkle filling material.

12. The method of claim 1 , further comprising admixing said platelet rich plasma with a cream or emulsion before said administering.

13. The method of claim 1 , wherein said administering comprises using at least one of a hydrogel of Albumin, a hydrogel resulting from reticulation of Albumin, or a hydrogel of polyethylene glycol, as a carrier to leave in contact with tissue for absorption of said platelet rich plasma.

14. The method of claim 1 , wherein said administering comprises filling a skin scar, a wrinkle line, or a fat deficiency of said patient with said platelet rich plasma.

15. The method of claim 1 , wherein said anticoagulant is a sodium citrate solution at 0.1 M.

16. The method of claim 15 , wherein said centrifugation tube contains 1 mL of said sodium citrate solution.

17. The method of claim 1 , wherein said thixotropic gel is a polymer-based thixotropic gel, and said centrifugation tube contains 3 mL of said polymer-based thixotropic gel.

18. The method of claim 1 , wherein said administering includes combining said platelet rich plasma with a bone filing material, a cream, an emulsion, or a co-agent selected from the group consisting of: a healing agent, a wrinkle filler, an anti-aging vitamin complex, an antibacterial agent, an antibiotic agent, a corticosteroid agent, an antalgic, an analgesic agent, an anesthetic agent, and adrenaline.

19. The method of claim 1 , further comprising providing a cell extract, said cell extract having dermal cells, keratinocytes, fibroblasts, melanocytes, Langerhans cells, fat cells, bone marrow cells, muscle cells, osteoblasts, chondrocytes, peiorsteal membrane cells, corneal cells, umbilical cord cells, Schwann cells, tendon cells, pancreas islet cells, adipocytes, adipose stem cells, corneal limbal stem cells, corneal keratinocytes, satellite stem cells, myoblast progenitor stem cells, stem cells, cartilage cells, ligament cells, connective tissue cells, or gingival cells; and

admixing said platelet rich plasma with said cell extract before said administering.

20. The method of claim 1 , wherein said thixotropic gel includes a polymer mixture.

21. The method of claim 1 , wherein said centrifugation tube is used to collect said blood in said withdrawing before said centrifuging step.

22. A method of treating a patient, said method comprising:

withdrawing blood from said patient;

centrifuging said blood in a centrifugation tube containing only two additives,

said two additives being an anticoagulant and a thixotropic gel to separate and obtain platelet rich plasma, wherein said centrifuging is performed one time in said method for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;

removing said platelet rich plasma obtained from said centrifugation tube;

mixing said platelet rich plasma with a hyaluronic acid to form a cell preparation; and

administering said cell preparation to said patient with an applicator device.

23. The method of claim 22 , wherein said mixing occurs at a treatment site of said patient.

24. The method of claim 22 , wherein said administering comprises applying a therapeutically effective amount of said cell preparation to tissue in said patient to promote tissue regeneration.

25. The method of claim 22 , wherein said centrifuging comprises centrifuging said tube at a force between 1500×g and 2000×g for 3 to 10 minutes.

26. The method of claim 22 , wherein said wherein said centrifuging comprises centrifuging said tube at a force of at least 1500×g for at least 8 minutes.

27. The method of claim 22 , further comprising separating said platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.

28. The method of claim 27 , further comprising re-suspending said platelet rich plasma in said tube, wherein said re-suspending follows said separating said platelet rich plasma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2018
From: TURZI, ANTOINE
To: REGENLAB USA LLC
Reel/Frame 045490/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2017
From: TURZI, ANTOINE; DU TOIT, DONALD FRANCOIS
To: TURZI, ANTOINE
Reel/Frame 044255/0465 →
Priority Claims (1)
WO PCT/EP2006/065493 · Aug 21, 2006 · international
Continuity (7)
Continuation 15605696 · May 25, 2017
Continuation 15369966 · Dec 6, 2016
Continuation 15044498 · Feb 16, 2016
Continuation 15044498 · Feb 16, 2016
Continuation 14021196 · Sep 9, 2013
Continuation 12438236
Related Publication 20180036346A1 · Feb 8, 2018